Clinical Trial Update: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing sequential and concurrent FOLFOXIRI/Bevacizumab regimens versus FOLFOX/Bevacizumab as first-line therapy in metastatic colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasms

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOX
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Colorectal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2017-09-18